Promising combo aims to beat relapsed leukemia
NCT ID NCT07039877
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding a low dose of venetoclax (a targeted drug) with itraconazole to standard chemotherapy can improve remission rates in people with relapsed or refractory acute lymphoblastic leukemia. The study enrolls 12 adults whose leukemia has returned or not responded to prior treatment. The goal is to achieve complete remission and prepare patients for a stem cell transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax (low dose) with itraconazole, plus TACL chemotherapy (asparaginase, dexamethasone, bortezomib, vincristine, mitoxantrone)
What this could lead to
If successful, this could offer a more effective treatment option for patients with relapsed/refractory acute lymphoblastic leukemia, potentially leading to remission and enabling stem cell transplant.
What could go wrong
This is a small, early-phase trial with only 12 participants, so results may not apply broadly. The combination may cause significant side effects, and the overall survival benefit is uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBKASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Universitario Dr. Jose E. Gonzalez
RECRUITINGMonterrey, Nuevo León, 64360, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact